Friday, August 14, 2026
Facts you can rely on·101 entities·4,806 sourced facts
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 6, 2026

Eli Lilly reports broad benefits for experimental obesity drug retatrutide

View original at seekingalpha.com
Eli Lilly reports broad benefits for experimental obesity drug retatrutide [Worried mature man measuring his waist in a living room] Ljupco/iStock via Getty Images Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]) on Saturday reported positive results from two late-stage clinical trials of its experimental obesity…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Up to 90% of type 2 diabetes patients receiving retatrutide achieved A1C below 7%; nearly half reached A1C below 5.7% (normal range)

    60% confidence
  • Retatrutide reduced knee osteoarthritis pain scores by as much as 73%

    60% confidence
  • Retatrutide reduced breathing interruptions in obstructive sleep apnea by up to 36.1 events per hour, representing roughly a 61% improvement

    60% confidence
  • More than 65% of highest-dose TRIUMPH-1 participants reduced BMI below 30, no longer meeting the medical definition of obesity

    60% confidence
  • Discontinuation rates due to side effects ranged from approximately 2% to 11% depending on study and dose level

    60% confidence
  • About one-third of highest-dose participants reached a BMI below 25, generally considered a healthy weight range

    60% confidence
  • Retatrutide improved triglycerides, non-HDL cholesterol, blood pressure, and waist circumference across both studies

    60% confidence
  • Highest-dose T2D patients lost average 36.6 pounds (16.8% body weight) and weight loss had not yet leveled off by study end

    60% confidence
  • In TRIUMPH-1, adults with obesity receiving the highest dose of retatrutide lost an average of 70.3 pounds (28.3% body weight) after 80 weeks

    60% confidence
  • In TRANSCEND-T2D-1, retatrutide reduced A1C levels by up to 2 percentage points over 40 weeks in type 2 diabetes patients starting at an average A1C of 7.9%

    60% confidence
  • GLP-1 drug market sales forecast raised to $150 billion

    60% confidence
  • Among more severely obese participants treated for two years, average weight loss reached 85 pounds (38.56 kg)

    60% confidence